Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotransplant(BTRN) -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (267)	5/25/1999 8:06:00 PM
From: scaram(o)uche	Read Replies (1) \| Respond to of 1475

Looks like bad news for MEDI/BTRN, but..... is it? I believe that LFA-3 is the only high affinity ligand for *CD2* identified to date in humans. LFA-3 has a wide tissue distribution, including non-hematopoietic cells such as endothelial cells, fibroblasts and erythrocytes. Since CD2 is expressed largely if not exclusively on cells of the T lymphocyte lineage and NK cells and all other factors equal (unlikely in biological systems), it is logical to guess ("assume" would be too strong) that it would take less anti-CD2 to block the CD2/LFA-3 interaction than it would take anti-LFA-3. In addition, there's the holy grail....... the MEDI release mentions it, but provides no further evidence. Looks like BGEN is ripping, and, from what I've seen, MEDI is merely sticking a toe in the water. It won't be boring! Thanks, PB........ biz.yahoo.com